| Literature DB >> 34676435 |
Fernanda Rodrigues Mendes1,2, Wellington Fernandes da Silva1,2, Raphael da Costa Bandeira de Melo1,3, Douglas Rafaele Almeida Silveira2,4, Elvira Deolinda Rodrigues Pereira Velloso1,3, Vanderson Rocha1,2,3, Eduardo Magalhaes Rego5,6,7.
Abstract
Despite advances in supportive measures, acute myeloid leukemia (AML) remission induction still has a high mortality rate in real-world studies as compared to prospective reports. We analyzed data from 206 AML adult patients treated with conventional chemotherapy. The primary endpoint was the 60-day mortality rate, aiming to find risk factors and to examine the role of anti-infection prophylaxis. The 60-day mortality rate was 26%, raising to 41% among those older than 60 years. Complete response was documented at the end of induction in 49%. The final survival model showed that age > 60 years (HR 3.2), Gram-negative colonization (HR 3), monocytic AML (HR 1.8), C-reactive protein (CRP) > 15 mg/dL (HR 10), and an adverse risk in the genetic stratification (HR 3) were associated with induction death. Multidrug-resistant bacteria colonization, thrombosis, and AKI were documented in 71%, 12%, and 66% of the cohort, respectively. Antibacterial and antifungal prophylaxis did not improve outcomes in this study. Our report corroborated the higher mortality during AML induction compared to real-world data from the USA and Europe. In line with other publications, age and cytogenetic stratification influenced early death in this cohort. Noticeably, Gram-negative colonization, monocytic AML, and CRP were also significant to early mortality.Entities:
Keywords: Acute myeloid leukemia; Early death; Induction remission; Intensive chemotherapy
Mesh:
Substances:
Year: 2021 PMID: 34676435 DOI: 10.1007/s00277-021-04687-6
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673